Evidence map›Paper›PMID 30200590›Full record

ArticleMedicines (Basel, Switzerland)2018

Clinical Safety of Combined Targeted and

Anja Thronicke, Shiao Li Oei, Antje Merkle, Harald Matthes, Friedemann Schad

Abstract read
In one paragraph

Article in Medicines (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Systematic analysis of mistletoe prescriptions in clinical studies.Journal of cancer research and clinical oncology · 2023
    Pooled it
  2. Cancer-related fatigue in patients treated with mistletoe extracts: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Pooled it
  3. Article
  4. Review
  5. Combined Immune Checkpoint Blockade and HelixorInternational journal of molecular sciences · 2025
    Article
  6. Article
  7. Safety of Combined Targeted and HelixorInternational journal of environmental research and public health · 2023
    Observational
  8. PluronicPharmaceutics · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies.Evidence-based complementary and alternative medicine : eCAM · 2019
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anja ThronickeNetwork Oncology, Research Institute Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany. anja.thronicke@havelhoehe.de.
Shiao Li OeiNetwork Oncology, Research Institute Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany. shiaoli.oei@havelhoehe.de.
Antje MerkleNetwork Oncology, Research Institute Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany. antje.merkle@havelhoehe.de.
Harald MatthesNetwork Oncology, Research Institute Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany. harald.matthes@havelhoehe.de.
Friedemann SchadNetwork Oncology, Research Institute Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany. fschad@havelhoehe.de.ORCID 0000-0002-6928-6209

Funding

Abnoba GmbH n.a.Helixor Heilmittel n.a.Iscador AG n.a.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

combinational therapyimmune checkpoint inhibitorsmonoclonal antibody therapysafety analysistargeted therapytoxicity profiletreatment discontinuationViscum album L.

Identifiers

PMID30200590
PMCPMC6164814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.